ADMA Biologics, Inc. (NASDAQ: ADMA) is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disorder (PIDD) and certain infectious diseases. The company’s product candidates target niche patient populations – including patients suffering from underlying immune deficiency diseases and patients who are immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a phase III clinical trial in patients with PIDD, and the company submitted a biologics license application to the FDA on July 31, 2015. For more information, visit the company’s website at www.admabiologics.com.